EASTLAND JULIA MARIE 4

What Happened Julia Eastland, CEO & President (also a Director) of Zentalis Pharmaceuticals (ZNTL), reported two sales of company stock. On 2026-02-06 she sold 7,866 shares at $2.43 each for $19,112, and on 2026-02-09 she sold 889 shares at $2.39 each for $2,127 — a total of 8,755 shares disposed for $21,239. The transactions are reported as sales (S).

Key Details

• Transaction dates and prices:
  • 2026-02-06: 7,866 shares @ $2.43 = $19,112
  • 2026-02-09: 889 shares @ $2.39 = $2,127
• Total disposed: 8,755 shares for $21,239.
• Transaction type: Reported as "open market or private sale" (code S).
• Shares owned after transaction: Not stated in the information provided in this summary.
• Footnote: The filing notes (F1) these sales were automatic transfers by the issuer to cover tax withholding on the vesting and settlement of previously granted restricted stock units (RSUs).
• Filing: Report filed 2026-02-10 covering transactions through 2026-02-09; no late filing flag indicated in the reported data.

Context These sales were executed to satisfy tax withholding obligations related to RSU vesting, per the issuer note — a routine administrative event rather than an independent, discretionary sale by the insider. Such tax-withholding disposals are common and do not necessarily signal the insider’s view on company prospects.